公开(公告)号：US20220016112A1

公开(公告)日：2022-01-20

申请号：US17368238

申请日：2021-07-06

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jianming Yu ,  In Jong Kim ,  Yat Sun Or

IPC: A61K31/498 ,  C07D491/107 ,  C07D519/00 ,  A61K45/06 ,  A61K31/4985 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20190040084A1

公开(公告)日：2019-02-07

申请号：US16100721

申请日：2018-08-10

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jianming Yu ,  Brian C. Shook ,  Thomas P. Blaisdell ,  In Jong Kim ,  Joseph Panarese ,  Kevin McGrath ,  Solymar Negretti-Emmanuelli ,  Yat Sun Or

IPC: C07D519/00 ,  A61K31/554 ,  C07D491/048 ,  A61K31/551 ,  A61K45/06 ,  A61K31/55 ,  C07D495/04 ,  A61K31/553

CPC classification number: C07D519/00 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  A61K45/06 ,  C07D401/06 ,  C07D401/14 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20180193352A1

公开(公告)日：2018-07-12

申请号：US15863216

申请日：2018-01-05

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Brian C. Shook ,  In Jong Kim ,  Jianming Yu ,  Thomas P. Blaisdell ,  Joseph Panarese ,  Yat Sun Or

IPC: A61K31/551 ,  A61P31/14 ,  C07D471/04 ,  C07D495/04

CPC classification number: A61K31/551 ,  A61P31/14 ,  C07D471/04 ,  C07D495/04

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: These compounds are useful for treating Respiratory Syncytial Virus (RSV) infection. The present invention further relates to pharmaceutical compositions comprising these compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the invention.

公开(公告)号：US20170226129A1

公开(公告)日：2017-08-10

申请号：US15405526

申请日：2017-01-13

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jianming Yu ,  Brian C. Shook ,  Thomas P. Blaisdell ,  In Jong Kim ,  Joseph Panarese ,  Kevin McGrath ,  Solymar Negretti-Emmanuelli ,  Yat Sun Or

IPC: C07D519/00 ,  A61K31/55 ,  A61K31/554 ,  A61K31/553 ,  A61K31/551 ,  C07D491/048 ,  C07D495/04 ,  A61K45/06

CPC classification number: C07D519/00 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  A61K45/06 ,  C07D401/06 ,  C07D401/14 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US12268694B2

公开(公告)日：2025-04-08

申请号：US17094029

申请日：2020-11-10

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Brian C. Shook ,  In Jong Kim ,  Thomas P. Blaisdell ,  Jianming Yu ,  Joseph Panarese ,  Kai Lin ,  Michael H. J. Rhodin ,  Nicole V. McAllister ,  Yat Sun Or

IPC: A61K31/5513 ,  A61K31/4439 ,  A61K31/7056 ,  A61K39/395 ,  A61K39/42 ,  A61K45/06 ,  A61P31/14 ,  C07D213/12 ,  C07D213/14 ,  C07D217/12 ,  C07D217/14 ,  C07D243/24 ,  C07D403/12 ,  C07D491/04 ,  C07D498/08 ,  C07K16/10

Abstract: The present invention relates to a pharmaceutical composition useful for treating a Respiratory Syncytial Virus (RSV) infection, comprising a compound which is or a pharmaceutically acceptable salt thereof, and a second anti-respiratory syncytial virus agent.

公开(公告)号：US20230087410A1

公开(公告)日：2023-03-23

申请号：US17735258

申请日：2022-05-03

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Brian C. Shook ,  In Jong Kim ,  Thomas P. Blaisdell ,  Jianming Yu ,  Joseph D. Panarese ,  Yat Sun Or

IPC: C07D513/04 ,  A61K45/06 ,  C07D495/04 ,  A61K31/56 ,  C07D498/08 ,  C07D413/14 ,  C07D413/12 ,  A61K31/58 ,  C07D243/16 ,  C07D471/08 ,  C07D491/048 ,  A61K31/5513 ,  C07D417/14

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US11572367B2

公开(公告)日：2023-02-07

申请号：US16930622

申请日：2020-07-16

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Adam Szymaniak ,  Kevin McGrath ,  Jianming Yu ,  Tyler Mann ,  Long Nguyen ,  Kaicheng Zhu ,  In Jong Kim ,  Yat Sun Or

IPC: C07D491/044 ,  C07D491/048 ,  C07D491/052 ,  C07D471/04

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US11254664B2

公开(公告)日：2022-02-22

申请号：US16821290

申请日：2020-03-17

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Kaicheng Zhu ,  Kevin McGrath ,  Solymar Negretti-Emmanuelli ,  Adam Szymaniak ,  Jianming Yu ,  In Jong Kim ,  Yat Sun Or

IPC: C07D243/12 ,  A61K31/55 ,  C07D413/14 ,  A61P31/14 ,  C07D417/14 ,  A61K45/06 ,  A61K31/5513

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US11091501B2

公开(公告)日：2021-08-17

申请号：US16023422

申请日：2018-06-29

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： In Jong Kim ,  Jianming Yu ,  Joseph Panarese ,  Kevin McGrath ,  Solymar Negretti-Emmanuelli ,  Thomas P. Blaisdell ,  Brian C. Shook ,  Yat Sun Or

IPC: A61K31/55 ,  C07D519/00 ,  C07D495/04 ,  A61P31/16

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US10881666B2

公开(公告)日：2021-01-05

申请号：US16145768

申请日：2018-09-28

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Brian C. Shook ,  In Jong Kim ,  Thomas P. Blaisdell ,  Jianming Yu ,  Joseph Panarese ,  Kai Lin ,  Michael H. J. Rhodin ,  Nicole V. McAllister ,  Yat Sun Or

IPC: A61K31/5513 ,  A61P31/14 ,  C07D491/04 ,  C07D213/12 ,  C07D213/14 ,  A61K31/7056 ,  A61K39/42 ,  A61K39/395 ,  C07D403/12 ,  C07K16/10 ,  C07D217/14 ,  C07D243/24 ,  A61K45/06 ,  C07D217/12 ,  A61K31/4439 ,  C07D498/08

Abstract: The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.